After the discovery of rare variants in KCNA2 as the cause of several types of epilepsy,9 4‐aminopyridine (4‐AP) emerged as an informed treatment choice with potentially specific value in KCNA2 gain‐of‐function‐related DEE,10 showing reversal of gain of function in vitro. Here, KCNA2 is linked to epilepsy.